<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
</head>
<body><p style="text-align:justify;"><span >Deep Vein Thrombosis (DVT) is a common disease although often asymptomatic. The deep veins of the lower limbs are affected most commonly, but thrombosis may affect other sites, including the upper limbs, intracranial and splanchnic veins. Complications include pulmonary thromboembolism, which can be life-threatening. It is therefore essential to have a reliable method for establishing the DVT risk of patients and to take active steps to provide prophylactic treatment as necessary. Common risk factors for DVT include obesity, smoking, prolonged immobility (e.g. bed rest, long haul flights), major surgery e.g. orthopaedic, abdominal and pelvic surgery, pregnancy and the puerperium, after caesarean section, malignancies, inherited blood disorders, oestrogen therapy and medical conditions, e.g. congestive cardiac failure, myocardial infarction, nephrotic syndrome, stroke, systemic lupus erythematosus.</span></p><p style="text-align:justify;"><span >In cases of confirmed DVT, treatment with anticoagulants must not be delayed unnecessarily unless there are significant contraindications to their use such as recent intracerebral bleed, severe liver disease, active peptic ulcer, bleeding disorders, and severe hypertension.</span></p><h3>CAUSES</h3><p> • Stagnation of blood in the vein</p><p> • Increased viscosity of blood</p><p> • Inflammation of the blood vessel causing damage</p><p><strong>SYMPTOMS</strong></p><p> • Swelling or firmness of affected limb (usually unilateral)</p><p> • Pain in the affected limb</p><p> • Mild fever</p><h3>SIGNS</h3><p> • Swelling of affected limb</p><p> • Differential warmth</p><p> • Tenderness</p><p> • Redness</p><p> • Pitting oedema</p><p> • Prominent superficial veins</p>
    <p>
        <div style="width: 95vw;">
            <img src="https://osamfrimpong.github.io/stg_app_web/images/wells_score_for_dvt.jpg" alt="Well's score interpretation for DVT" style="max-width: 100%;height: auto;margin: auto;">
            </div>
    </p>
    
    <h3>INVESTIGATIONS</h3><p> • D-Dimer test</p><p> • Doppler ultrasound</p><p> • Thrombophilia screen e.g.protein C, proteinS levels (in patients with recurrent DVT)</p><p> • FBC</p><p> </p><h3>TREATMENT</h3><p><strong>Treatment objectives</strong></p><ul><li>To prevent clot propagation and pulmonary embolism</li><li>To prevent recurrence</li></ul><h3>Non-pharmacological treatment</h3><ul><li>Avoidance of prolonged recumbency and dehydration</li><li>Avoidance of excess amounts of coffee, tea and alcohol, especially on long journeys</li><li>Increase water intake during long journeys or periods of immobility</li><li style="text-align:justify;">Regular exercise during long journeys e.g. stopping on road journeys to take a walk or moving about on a plane during long flights and leg flexing exercises while seated</li><li style="text-align:justify;">Avoid crossing legs for long periods on long journeys</li><li style="text-align:justify;">Use of elastic compression stockings</li></ul><h3 style="text-align:justify;">Pharmacological treatment</h3><p style="text-align:justify;"><span ><strong>A. DVT Prophylaxis</strong></span></p><p><span ><strong>1<sup>st</sup> Line treatment Evidence Rating: [A]</strong></span></p><ul><li>Heparin, SC,</li></ul><p><strong><u>Adults</u></strong></p><p>5,000 units 8-12 hourly</p><p><strong><u>Children</u></strong></p><p>1 month-18 years; 250 units/kg 12 hourly</p><p><span ><strong>2<sup>nd</sup> Line Treatment Evidence Rating: [A]</strong></span></p><ul><li>Enoxaparin, SC,</li></ul><p><strong><u>Adults</u></strong></p><p>40 mg daily</p><p><strong><u>Children</u></strong></p><p>2 months-18 years; 500 microgram /kg 12 hourly (max 40 mg)</p><p>1-2 months; 750 microgram /kg 12 hourly</p><h3><span >B.  DVT Treatment</span></h3><p><span ><strong>1<sup>st</sup> Line Treatment Evidence Rating: [A]</strong></span></p><ul><li>Heparin, SC,</li></ul><p><strong><u>Children</u></strong></p><p>1 month-18 years; 250 units /kg 12 hourly</p><h3>Or</h3><ul><li>Heparin, IV,</li></ul><p><strong><u>Adults</u></strong></p><p>80 units/kg stat. continue with 18 units/kg / hour</p><h3>Or</h3><p>250 units/kg, SC, continue with 250 units /kg 12 hourly</p><p><strong><u>Children</u></strong></p><p><strong>1-18 years; </strong>75 units/kg stat. continue with 20 units/kg/hour</p><p><strong>1 month-1 year; </strong>75 units/kg stat. continue with 25 units/kg/ hour</p><p><strong><u>Neonates</u> (term baby); </strong>75 units/kg stat. continue with 25 units/kg/ hour</p><p><strong><u>Neonates</u> (&lt; 35 weeks); </strong>50 Units /kg stat. continue with 25 units/ kg/hour</p><p><span ><strong>2<sup>nd</sup> Line Treatment Evidence Rating: [A]</strong></span></p><ul><li>Enoxaparin, SC,</li></ul><p><strong><u>Adults</u></strong></p><p>1.5 mg/kg (150 units/kg) daily</p><p><strong><u>Children</u></strong></p><p>2 months-18 years; 1 mg/kg 12 hourly</p><p>1-2 months;1.5 mg/kg 12 hourly</p><p><u>Neonates</u>;  1.5-2 mg/kg 12 hourly</p><h3>Or</h3><ul><li>Dalteparin, SC,</li></ul><p><strong><u>Adults</u></strong></p><p>200 mg/kg (max. of 18,000 units) daily</p><p><strong><u>Children</u></strong></p><p>12-18 years; 200 units/kg once daily (max 18,000 units daily)</p><p>1 month-12 years;100 units/kg 12 hourly</p><p><u>Neonates</u>; 100 units/kg 12 hourly</p><p><span ><strong>And</strong></span></p><p> • Warfarin, oral,<u> </u></p><p><strong><u>Adults</u> </strong></p><p>Loading Dose</p><p> </p><h3>REFERRAL CRITERIA</h3><p><span >Refer to physician specialist for management and monitoring.</span></p>
</body>
</html>
